Get the Stockscreener App
0.3552
5.53%
-0.0208
After Hours:
.35
-0.0052
-1.46%
Oragenics Inc stock is traded at $0.3552, with a volume of 1.36M.
It is down -5.53% in the last 24 hours and up +23.33% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.376
Open:
$0.3777
24h Volume:
1.36M
Relative Volume:
1.92
Market Cap:
$4.34M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.0609
EPS:
-5.83
Net Cash Flow:
$-8.25M
1W Performance:
+7.64%
1M Performance:
+23.33%
6M Performance:
-75.50%
1Y Performance:
-93.02%
1-Day Range:
$0.3199
$0.395
1-Week Range:
$0.3199
$0.448
52-Week Range:
$0.2542
$7.74
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.3552 | 4.34M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oragenics Inc Stock (OGEN) Latest News
Oragenics Simplifies Capital Structure and Advances Strategy - TipRanks
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - The Manila Times
Oragenics Strengthens Balance Sheet: $2.35M Preferred Share Conversion Streamlines Capital Structure - StockTitan
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics director Alan Dunton sells $23 in common stock By Investing.com - Investing.com Canada
Oragenics director Alan Dunton sells $23 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock By Investing.com - Investing.com UK
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2024. - Marketscreener.com
Oragenics announces termination of president's employment agreement By Investing.com - Investing.com South Africa
Oragenics announces termination of president's employment agreement - Investing.com India
Oragenics : Termination of Material Agreement Form 8 K - Marketscreener.com
Mice Model Market: Global Type, Trends, Service, Growth, - openPR
OGEN Stock Plummets to 52-Week Low at $0.28 Amid Steep Decline - Investing.com Australia
OGEN Stock Plummets to 52-Week Low at $0.28 Amid Steep Decline By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com India
Oragenics: Q3 Earnings Snapshot - The Pioneer
Oral Probiotics Supplements Market Expected to Experience - openPR
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World
SEC Form DEF 14A filed by Oragenics Inc. - Quantisnow
OGEN stock plunges to 52-week low, touches $0.28 By Investing.com - Investing.com Australia
OGEN stock plunges to 52-week low, touches $0.28 - Investing.com
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury
Oragenics, Inc. to Present at the Centurion One Capital 2nd Annual Bahamas Summit - Marketscreener.com
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - GlobeNewswire
Check Out Oragenics Inc (OGEN)’s Trade Data Rather Than the Analysts’ Views - SETE News
Oragenics Shares Investor Presentation Online - TipRanks
Oragenics inks sales agreement for at-the-market stock offering - Investing.com
Oragenics inks sales agreement for at-the-market stock offering By Investing.com - Investing.com South Africa
Oragenics Inc (OGEN) stock analysis: A comprehensive overview - US Post News
The Future of Oragenics Inc: Analyzing OGEN - The InvestChronicle
Oragenics advances concussion treatment with ONP-002 By Investing.com - Investing.com South Africa
Oragenics advances concussion treatment with ONP-002 - Investing.com India
Metric Deep Dive: Understanding Oragenics Inc (OGEN) Through its Ratios - The Dwinnex
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation - GlobeNewswire
OGEN stock touches 52-week low at $0.37 amid sharp annual decline - Investing.com India
OGEN’s valuation metrics: A comprehensive analysis - US Post News
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):